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Normal arterioles, in contrast to the abnormal microvasculature of many solid tumors, provide a 
target for selective drug action that can enhance local heat treatment of the tumors. 
Measurements of tissue blood flow with radioactive microspheres and estimates of changes in 
blood flow with thermal clearance methods revealed that vasodilator drugs either decreased or 
did not alter blood flow in hamster melanoma, rat hepatoma, and canine transmissible venereal 
tumor, while increasing perfusion in adjacent normal tissues 2 to 4-fold. Solutions of the bio-heat 
transfer equation, which take into account such selective effects of vasodilators on blood flow in 
normal tissues, clearly demonstrate improved selective heating for spheroidal tumors over 2 cm 
in diameter. In the presence of vasodilator drug effect, steady-state center tumor temperatures of 
45-50°C can be achieved by increased power input, while surrounding normal tissues remain 
below 42°C.  
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Heat therapy for cancer is a promising adjunct or alternative to radiation and chemotherapy [l-6]. 
During local heat therapy, as opposed to whole-body hyperthermia, core body temperature 
remains close to normal, and so the circulation of blood tends to cool the heated region. The 
ability to produce selective local temperature elevations in solid tumors in vivo is related to 
differences in vascularization and blood flow between tumor tissues and normal tissues [6-9]. 
 
The principal difference between the microcirculation of solid tumors and that of normal tissues 
is the abundance of sinusoidal capillary beds in solid tumors. These capillary sinusoids are 
broader, longer, and separated by larger intercapillary distances than normal capillaries [10-16]. 
These vessels penetrate neoplastic tissues in response to a chemical tumor angiogenesis factor 
(TAF) liberated by tumor cells [17]. TAF appears to stimulate the growth of such capillaries but 
not to stimulate the development of capillary sprouts into well differentiated, larger-caliber 
arterioles. Consequently, the density of arteries and arterioles in tumor tissues is abnormally 
small in relation to the venous vasculature [15, 16, 18]. The arterial vessels nourishing a tumor 
exhibit little vasomotion [19] and seem to be maximally dilated during tumor growth [16, 20]. 
 
If solid tumors are nourished by maximally dilated vessels feeding capillary sinusoids with 
poorly developed smooth muscle walls, then it is likely that the tumor vascular bed offers a 
relatively fixed resistance to blood flow. We reasoned, therefore, as have LeVeen et al. [3], that 
vasoactive drugs, which affect normal vascular smooth muscle, might be employed to change the 
ratio of tumor to normal tissue perfusion. This concept is presented by means of the electrical 
analogy in Fig. 1. In the figure the variable resistor (R1) denotes normally reactive arterioles and 
the fixed resistor (R2) denotes tumor vessels. The series resistance (Rs) denotes the normal 
arterioles which branch to feed both tumor and normal vessels. If a pump (the heart) feeds the 
parallel normal and tumor tissue beds, dilation of the normal vessels will create an effective 
arteriovenous shunt around the tumor. Flow to normal tissue will increase and flow to the tumor 
will tend to decrease. During local heat therapy, such changes in the distribution of blood flow 
would enhance cooling of normal tissues and simultaneously reduce cooling of the tumor. 
Consequently, more power can be applied to the tumor-bearing region, causing greater 
temperature elevations in the tumor, while surrounding normal tissues remain at a safe 
temperature. 
 
Accordingly, we wondered if it is reasonable, on the basis of known physics, that blood flow 
changes caused by vasodilators might be exploited to enhance therapeutic temperature 
differences between tumor and adjacent normal tissues during local heat therapy. To answer this 
question we first studied the effects of vasodilators on the ratio of normal perfusion to tumor 
perfusion in three species of animals bearing different tumor types. Then we used computer 
programs to solve the bio-heat transfer equation for temperature distributions in and around 
spherical tumor models as a function of blood flow. Such computations provide pictures of 
complete temperature distributions in space, which are difficult to appreciate from the few values 
of temperature at specific points that can be obtained experimentally. Moreover, computer 
models allow easy study of the effects of tumor size and the distribution of blood flow in order to 







Fig. 1. Electrical analogy of tumor vs. normal blood flow. Arrows indicate variable 
resistances subject to drug action. 
 
 
THEORETICAL CONSIDERATIONS AND COMPUTATIONAL METHODS 
 
During local hyperthermia therapy, heat is deposited in the tissue by the tissue’s own metabolism 
and to a much greater extent by the external energy source. Heat leaves the tissue as a result of 
thermal diffusion (conduction) and as a result of tissue perfusion with arterial blood, which 
remains approximately at core body temperature. Classically, this heat balance in tissue is 
described by the bio-heat transfer equations [8, 21-23], which serves as the basis for our 
theoretical computations. 
 
The bio-heat equation 
 
Consider a small volume of tissue which is being heated by an external energy source. This 
‘control volume’ is small enough that its thermal properties are uniform. The conservation of 
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qm = metabolic heat generation (W/cm
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Considering the terms from left to right, the first represents the net heat transfer out of the control 
volume by conduction, the flow of heat by molecular action due to a thermal gradient. The 
second term represents heat loss due to blood perfusion, assuming that blood in the smaller 
vessels comes into thermal equilibrium with surrounding tissues. (Chen and Holmes [22] have 
scrutinized this assumption and found it to be essentially valid for tissues that are not close to 
very large blood vessels.) The third and fourth terms represent heat gain due to exothermic 
metabolism, qm , and power input from an external source P. In the local heat therapy of tumors, 
P is much greater than qm . The right-hand term represents the change in internal energy of the 
tissue when its temperature changes with time. Under steady-state conditions, in which 
temperature is constant (dT/dt = 0), this last term is zero, so that the heat loss from conduction 
and blood perfusion exactly balances heat gain from metabolic and external sources. If heat gain 





The simplest clinically realistic solution of the bio-heat equation, which has been studied by 
others [21], describes a spherical tumor surrounded by a single type of normal tissue (Fig. 2). 



























for steady-state conditions and uniform thermal conductivity. The variable, r, indicates radial 
distance from the center of the tumor. Blood perfusion (r) and power absorption P(r) are 
specified functions of r. In the model of Fig. 2, a spherical tumor of radius  r  is treated by local 
heat therapy. Power is deposited from an external source to a radial distance rRx greater than the 
radius of the tumor. A large shell of unheated normal tissue extends to radius R0, beyond which 
the temperature will no longer change. The metabolic heat generation qm is either considered to 







Fig. 2. Sketch of spherical tumor model used in computations. 
 
 
To solve the bio-heat equation for steady-state temperature profiles in and around the tumor, we 
implemented a finite-difference routine with a mesh size of 200 nodes, using standard 
computation techniques [24]. The functions (r) and P(r) were represented by twenty-five 
discrete levels. The remaining thermophysical properties required in the solution (cb and k) were 
taken, for convenience, to have values corresponding to water (k = 0.6 W/m-
o
C,  
cb = 4179 J/kg-
o
C). In any specific numerical solution of the bio-heat equation one must also 
specify the size (radius) of the tumor, the blood flow in and around the tumor, and the radius of 
the treated region. In addition, one must specify the presumed effect of vasodilator drugs on the 
distribution of blood flow. These considerations led us to animal studies of the influence of 





Estimation of vasodilator effects on perfusion from temperature-time curves 
 
In addition to providing a basis for calculation of temperature profiles in and around a heated 
tumor, the bio-heat equation provides a rationale for estimating the effects of vasoactive drugs on 
blood flow. Consider an experiment in which one records tumor and normal tissue temperatures 
continuously during or after local heating, while a rapidly-acting vasodilator drug is injected. 
From the bio-heat equation for steady-state conditions with a prescribed perfusion, there will be 
no change in tissue temperature with time. However, if the perfusion rate is suddenly changed, 
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from the change in the slope of the temperature- time curve [dT/dt] produced by injection of the 
rapidly-acting drug. This expression is based upon the assumption that the conduction and heat 
deposition terms of the bio-heat equation are not immediately changed by drug injection and that 
the observed slope change is entirely due to the drug effects upon perfusion. 
 
In the present studies, we recorded tumor and normal tissue temperatures continuously after a 
brief period of radiofrequency (RF) heating. Using this technique we studied two of the three 
tumor models to be described subsequently: a transplantable melanoma in Golden Syrian 
hamsters and the much larger transplantable transmissible venereal tumor in mongrel dogs. The 
rapidly-acting vasodilators included intravenous sodium nitroprusside in the hamsters and 
acetylcholine chloride infused into the femoral artery nourishing the tumor bearing hind limbs of 
the dogs. We then estimated the drug-induced change in perfusion, , from the slope changes 
of tissue temperature-time curves for tumor and for adjacent muscle tissue, taking specific heat 
and density values as those of water and taking core (esophageal) temperature as a measure of 
arterial blood temperature. These data provided one estimate of the relative effect of the 
vasodilators on perfusion in tumor tissues as compared to normal tissues. 
 
Microsphere technique for estimation of local blood flow  
 
In another series of experiments, we used the tracer microsphere technique to provide a second, 
independent measure of the effects of vasodilators on the distribution of perfusion between 
tumor and normal tissues. The use of microspheres to measure tumor blood flow is reasonably 
well established [7, 25-27]. In this study, radioactively labeled polystyrene microspheres, 15 m 
in diameter, containing one of four different gamma-emitting labels, were employed, according 
to the method of Heymann et al. [28]. To measure regional blood flow in peripheral tissues, a 
well-mixed suspension of microspheres was injected rapidly into the left ventricle of an 
anesthetized, tumor-bearing dog or rat. In the dogs, a commercial pigtail catheter with multiple 
side-holes (Cook, Inc., Bloomington, Indiana, U.S.A.) was placed in the left ventricle via the 
right common carotid artery for injection of microspheres. 
 
In the rats, a PE 50 polyethylene catheter was placed into the left ventricle via the right common 
carotid artery for injection of microspheres. The catheter used in the rats had a closed end and six 
side-holes to promote good mixing of the microspheres with blood. A ‘surrogate organ’ 
reference blood sample was collected from the femoral artery (in rats) or the brachial artery (in 
7 
 
dogs) at a measured, constant flow rate, starting before the microspheres were injected and 
continuing until well after their entrapment in systemic vascular beds. 
 
After the experiment the animal was killed and samples of tumor and normal tissues were 
excised and weighed. Radioactivity (counts/min) in the tissue samples and the ‘surrogate organ’ 
blood samples was measured by a Beckman 8000 gamma-spectrophotometer. Total flow (cardiac 
output) was calculated from the measured activity (counts/min) according to the relationship:  
 
        total flow                             surrogate organ flow 
-------------------------     =      ------------------------------------ . 
counts/min injected                 surrogate organ counts/min 
 
Regional blood flows to the tumor and normal tissue samples were calculated according to the 
relationship: 
 
        tissue flow                             surrogate organ flow 
-------------------------     =      ------------------------------------ . 





To gain some appreciation for the generality of vasodilator effects, we studied three different 
vasodilators in three different transplantable tumor models.  
 
Hamster melanoma. Subcutaneous nodules of a transplantable melanoma [29] were grown in 
the hind limbs of 93 to 104-g outbred Golden Syrian hamsters of either sex (obtained from 
Harlan Sprague Dawley, Inc., Madison, Wisconsin, U.S.A.), and tumors weighing 1.8-4.7 g were 
heated with 500 kHz radiofrequency current via gel pad electrodes (Fig. 3). This moderately 
slow growing melanotic melanoma was obtained from the American Type Culture Collection 
(Rockville, Maryland, U.S.A.). Tumor cells were grown at 37°C in McCoy’s 5A medium (Gibco 
Co., Grand Island, New York, U.S.A.), supplemented with penicillin (100 units/ml), 
streptomycin (0.1 mg/ml) and fetal calf serum (20% v/v). The cells were maintained in 
monolayer cultures in 75-cm
2
 plastic flasks. Hamsters were injected subcutaneously in the right 
rear leg with 1 x 10
6
 melanoma cells suspended in 0.05 ml of the previously described medium. 






Fig. 3. Temperature probes in hamster leg heated with gel pad electrodes. 
 
 
After induction of anesthesia with sodium pentobarbital (30 mg/kg, i.p.), hollow glass 
microprobes, 1 mm in external diameter, were advanced into the center of the tumor nodule and 
into underlying skeletal muscle of the limb at right angles to the current field lines (Fig. 3). 
Thermistor probes could then be advanced into the microprobes to measure tissue temperatures, 
which were graphically displayed on a stripchart recorder. The jugular vein of the hamster was 
exposed to permit injection of sodium nitroprusside (1 mg/kg), a potent, direct acting vasodilator, 
or saline vehicle (0.1 ml) as a control. 
 
With this animal preparation we obtained artifact-free records of tumor and muscle tissue 
temperatures during periods of 500 kHz RF heating and could observe the transient effects of 
bolus injections of nitroprusside. The changes in effective perfusion, seen for several minutes 
after drug injection, were calculated from the drug-induced slope changes of the temperature-
time curves, as previously described. 
 
Rat hepatomas. Studies using radioactive microspheres were conducted in two types of 
transplantable rat hepatoma. The two types of tumor differed greatly in their vasculatures as seen 
under the light microscope. The first, which we called the ‘hard’ tumor, contained infrequent 
discrete, thin-walled capillaries. The second, which we called the ‘soft’ tumor, contained 
abundant wide sinusoidal spaces, filled with blood. Both tumor types diverged from a hepatoma 
which first appeared in a rat being fed the carcinogen FAA (N-2- fluorenylacetamide) [30]. To 
transplant these tumors into the recipient Harlan Fischer rats, a tumor was excised from a donor 
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rat and minced into l mm
3
 pieces. Two to four pieces were then implanted subcutaneously into 
the left thigh using a trocar needle. A growing period of two to three weeks was required.  
 
Thirty-four male Harlan Fischer rats with body weights ranging from 150 to 250 g, with 4.3 to 
21.9 g tumor nodules on the left leg, were used for this study, 12 bearing the hard tumor and 22 
bearing the soft tumor. The animals were first anesthetized with ketamine (0.2 g/kg i.m.). 
Radioactive microspheres were used to determine the blood flow in tumor and surrounding 
normal tissues. Two groups of rats were studied: rats given the vasodilator hydralazine, 0.5 
mg/kg i.v., and rats given 0.2 ml of 0.9% saline vehicle as a control.  
 
Canine transmissible venereal tumor. The well known effects of tumor size on tumor blood 
flow [7, 11, 31] and preliminary results of computer modeling showing the effects of tumor size 
upon temperature distribution [8] led us to investigate a larger animal model. The transmissible 
venereal tumor (TVT) is a naturally occurring neoplasm of the penis and vagina in dogs. 
Transmission from animal to animal occurs during coitus. The biology and mechanism of 
transmission of TVT in dogs have been previously reported by several investigators [32-36]. 
Tumors can be seeded in experimental animals by hypodermic injection of TVT cell suspensions 
and will grow rapidly in locations where they would not often occur in nature. 
 
We initiated TVTs in the subcutaneous tissue of the hind limbs in 10 dogs, using the technique of 
Epstein and Bennett [35] and Cohen [33]. After a growing period of 40-80 days, anesthesia was 
induced with thiopental sodium (~10 mg/kg) and maintained with methoxyfluorane, nitrous 
oxide and oxygen inhalation. In 3 dogs intra-arterial acetylcholine, which has a rapid onset of 
action, was infused via a catheter in the abdominal aorta at 100 mg/kg/min to produce local 
vasodilation in the tumor-bearing hind limb. In the remaining 7 dogs intravenous hydralazine 
(0.5 mg/kg) was given as a single bolus and blood flow determined 20 min later, when effects of 
the drug on blood pressure had stabilized. 
 
Local heating of the tumor-bearing limb on one side was accomplished with the use of a pair of 
Helmholtz coils of radius 8 cm and a Bircher electrosurgery/diathermy generator operating at 
13.56 MHz. Heating was done during intermittent 1 to 3 minute periods, between which 
temperatures of the tumor and of underlying normal muscle were recorded using Yellow Springs 
Instruments thermistor probes, calibrated against a mercury thermometer traceable to the U.S. 
National Bureau of Standards. In the 3 dogs given acetylcholine, changes in tumor and normal 
tissue perfusion caused by the drug were estimated from the slope changes of the temperature-
time curves. In the 7 animals given hydralazine, tissue perfusion was estimated using the 








Vasodilator effects on blood flow 
 
Tables 1A and 1B present effects of vasodilators upon tumor and normal tissue perfusion. Table 
1A presents changes in blood perfusion caused by drug treatment; Table 1B presents absolute 
values of blood perfusion before and after drug treatment. By either measure, blood perfusion in 
normal tissues increased after vasodilator injection, and blood perfusion of tumor tissue either 





Table 1A. Vasodilator influence on blood flow determined from analysis  







Table 1B. Influence of hydralazine (0.5 mg/kg iv.) on blood flow determined 




The results obtained with two different and independent techniques are substantially in 
agreement and yield a similar picture of the blood flow redistribution caused by vasodilator 
drugs. All three vasodilator drugs selectively improved blood flow to normal tissues. Typically, 
it appears that without vasodilator effect, both tumor and normal tissue perfusion in anesthetized 
animals lie in the neighborhood of 0.2 ml/min/g. After treatment with vasodilators normal tissue 
perfusion increased about 2 to 4-fold, while tumor flow either remained the same or decreased. 
These data allowed us to proceed to estimate the effects of vasodilator treatment upon tumor 
temperature profiles using the bio-heat equation. 
 
Computed effects of vasodilators on temperature profiles 
 
Considering published work of others describing tumor blood flow [20, 31, 37, 38] and our own 
observations of the redistribution of tumor blood flow by vasoactive drugs, we chose as a starting 
point the following specific conditions for modeling steady-state temperature profiles before and 
after administration of vasodilator drugs. Tumor radius: 5, 10, 20 or 40 mm. Power deposition: 
uniform in intensity and extending from the center of the tumor to twice the radius of the tumor. 
Initial tumor flow: equal to normal tissue flow, 0.2 ml/min/g. Drug effect: 2 x or 4x increase in 
normal tissue flow with no change in tumor flow and an abrupt, linear transition to normal tissue 
flow in the outer shell of the tumor. We evaluated the bio-heat equation for these conditions to 
determine the probable effect of vasodilators on the temperature distributions in and around 
tumors of various sizes during local heat therapy. Then we studied the influence of alternative 
assumptions for a 20 mm radius tumor, including (a) reduced blood flow within the tumor itself 
caused by vasodilators, in addition to increased flow in normal tissue, and (b) the existence of a 
hyperperfused outer shell in the tumor. In all of these computations the value of uniform power 
input was adjusted--as one would hope to do in practice-to keep the normal tissue at the edge of 




Calculated temperature profiles and tumor size 
 
Figures 4 A-D show temperature profiles computed from the bio-heat equation for 5, 10, 20 and 
40-mm radius tumors.  Tumor blood flow is always 0.20 ml/min/g. The solid curves represent 
control conditions in which blood flow in surrounding normal tissue is also 0.20 ml/min/g. The 
dashed and dotted lines represent two plausible levels of vasodilator effect, in which normal 
tissue perfusion is twice or four times tumor perfusion (0.40 or 0.80 ml/min/g). Central tumor 
temperatures approaching 10°C greater than core temperature and over 5°C greater than 
surrounding normal tissue can be achieved in this tumor model during typical vasodilator action.  
 
Clearly, tumor temperature increases as a function of the tumor radius when blood flow is greater 
in normal tissue than in tumor tissue. This result is easily understood. Heat is deposited 
uniformly in the tumor volume (proportional to r
3
), but under conditions of relatively low tumor 
blood flow a significant amount of ‘heat leaves by conduction through the tumor surface 
(proportional to r
2
). Hence the ratio of heat input to heat output, which determines tumor 




, and it follows that the effectiveness of 






















      
 
Fig. 4. Temperature profiles computed from the bio-heat equation for: A, 5; B, 10; C, 20; and 
D, 40-mm radius tumors surrounded by homogeneous normal tissue. r0 is the tumor radius; 
rRx is the treatment radius. Tumor perfusion is always 0.20 ml/min/g. In A power input was 
0.17412. 0.22622 and 0.31102 W/ml for blood flows of 0.20, 0.40 and 0.80 ml/min/g in 
surrounding normal tissue. In B power input was 0.09564, 0.13564 and 0.20188 W/ml for 
blood flows of 0.20, 0.40 and 0.80 ml/min/g in surrounding normal tissue. In C power input 
was 0.07358, 0.10857 and 0.16035 W/ml for blood flows of 0.20, 0.40 and 0.80 ml/min/g in 
surrounding normal tissue. In D power input was 0.06981, 0.10027 and 0.14062 W/ml for 





Variation of blood flow 
 
The effect is similar for other plausible combinations of tumor flow and vasodilator-enhanced 
normal tissue flow presented in Table 2. The table gives predicted center temperatures during 
vasodilator enhanced local heat therapy for various flow conditions. Also presented are the 
temperature gradients at the edge of the tumors, which are measures of the selectivity of heat 
therapy. Whenever tumor flow is relatively low compared to flow in normal tissues, there can be 
greater power input to the treated region without excessive temperature elevation in normal 
tissues. As a result, the tumor temperature rises toward cytotoxic levels, and steep temperature 
gradients in the neighborhood of 0.5 
o
C/mm radial distance can be established at the tumor 
edge.  
 
Table 2. Calculated center tumor temperatures during vasodilator enhanced 





Spatial profile of perfusion 
 
The existence of a hyperfused outer shell has been described in at least some tumor types [14, 
17, 39] and may be evident as a hypervascularized surface of many solid tumors at surgery. 
Figure 5 presents perfusion and steady-state temperature profiles during local heat therapy in a 
20-mm radius tumor model with an underperfused core and a hyperperfused outer shell. Curve A 
represents the base conditions and curve B represents the hypothetical effect of a vasodilator that 
increases flow in the outer shell of the tumor as well as in adjacent normal tissue. Contrary, 
perhaps, to intuition, the presence of a relatively well-perfused tumor shell permits greater power 
input to the tumor core and higher overall tumor temperatures while the tumor edge is 







Fig. 5. Perfusion and temperature profiles in a 40-mm diameter tumor model with 







Vasodilators have profound effects upon the distribution of blood flow between tumor and 
adjacent normal tissues. Dilation of normal arterioles improves blood flow in normal tissues and 
may shunt blood away from the tumor. According to the physical laws of heat transfer, such 
perfusion effects can greatly enhance the temperature difference between the tumor and adjacent 
normal tissues during local hyperthermia therapy. Our experimental studies involving three 
species, three tumor types and three different vasodilators show that such drugs can increase 
regional blood flow in normal tissues to several times that in tumor tissue, making possible 
steady-state intratumor temperatures of over 45°C while temperatures in surrounding normal 
tissues remain near 40°C. Temperature elevations of this magnitude are sufficient to produce 
tumor necrosis in a single treatment session lasting less than 1 hr [40, 41]. This influence of 
vasodilators upon the calculated temperature distributions is especially pronounced for larger 
tumor masses.  
 
Clinically, Jonsson and associates [42] studied the effects of intra-arterial prostaglandin El, a 
potent vasodilator, as an adjuvant to angiography of tumors of the extremities in 10 patients. 
Except in one case, involving a hemangioma, the arteriographic visualization of tumor vessels 
and delineation of the extent of disease were worse after the use of prostaglandin E1, while 
visualization of small normal muscular arteries improved. Evidently, prostaglandin increased 
blood flow in normal tissues relative to the tumor in a manner similar to the action of 
vasodilators reported in the present paper. In principle, such vascular effects are capable of 
increasing the therapeutic ratio (tumor temperature rise/normal tissue temperature rise) several 
fold to the point where a large proportion of the tumor tissue can be selectively destroyed by 
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